Influence of gender and oral contraceptive steroids on the metabolism of salicylic acid and acetylsalicylic acid

British Journal of Clinical Pharmacology
J O MinersD J Birkett

Abstract

Salicylic acid and acetylsalicylic acid (aspirin) disposition after an oral dose of aspirin, 900 mg (equivalent to 689.7 mg of salicylic acid) was studied in eight males, eight females and eight females receiving oral contraceptive steroids (OCS). Salicylic acid clearance was 61% higher in males compared to the control female group, an effect due largely to enhanced activity of the glycine conjugation pathway (salicyluric acid formation) in males. Salicylic acid clearance was 41% higher in OCS-users compared to the control female group due to increases in both the glycine and glucuronic acid conjugation pathways in the pill users. There was no difference in any salicylic acid disposition parameter between males and OCS-users. Area under the plasma concentration-time curve (AUC) and elimination half-life of aspirin was significantly greater and aspirin plasma hydrolysis rate was significantly lower in both female groups compared to males. There was no difference between OCS-users and the control female group in any of these parameters. Aspirin AUC and elimination half-life were significantly correlated with aspirin plasma hydrolysis rate. These data confirm the importance of hormonal factors in the regulation of drug conjugation...Continue Reading

References

Jul 1, 1979·Clinical Pharmacology and Therapeutics·D J GreenblattR I Shader
Jan 1, 1979·Drug Metabolism Reviews·G Levy
Mar 1, 1979·Clinical Pharmacokinetics·R EkstrandO Borga
Aug 1, 1979·Journal of Pharmaceutical Sciences·L Z Benet, R L Galeazzi
Oct 1, 1977·Clinical Pharmacology and Therapeutics·G G GrahamP D Paull
Dec 15, 1977·Clinica Chimica Acta; International Journal of Clinical Chemistry·J D Gupta, V Gupta
May 1, 1985·British Journal of Clinical Pharmacology·P C HoV J Heazlewood
Jan 1, 1985·European Journal of Clinical Pharmacology·L J LeskoN R Cutler
Jan 1, 1974·European Journal of Clinical Pharmacology·A WindorferR Urbanek
Apr 18, 1970·The Medical Journal of Australia·J M Duggan, B L Chapman
Jan 1, 1970·Biochemical Pharmacology·S L Tishler, P Goldman
May 1, 1968·Annals of Internal Medicine·M Samter, R F Beers
Jul 1, 1965·Journal of Pharmaceutical Sciences·G Levy
Nov 8, 1965·JAMA : the Journal of the American Medical Association·J R Klinenberg, F Miller
Oct 1, 1981·Journal of Pharmaceutical Sciences·M DivollR I Shader
May 1, 1983·Clinical Pharmacology and Therapeutics·D R AbernethyR I Shader
Nov 1, 1984·Clinical Pharmacology and Therapeutics·G P StoehrR B Smith
Jun 1, 1984·British Journal of Clinical Pharmacology·R A SeymourM D Rawlins
Nov 1, 1983·British Journal of Clinical Pharmacology·J O MinersD J Birkett
Oct 1, 1983·Clinical Pharmacology and Therapeutics·S H DromgooleH E Paulus
Jul 1, 1983·Clinical Pharmacology and Therapeutics·M C MitchellS Schenker
Jan 1, 1982·Clinical Pharmacology and Therapeutics·S L MiaskiewiczE S Vesell
Jul 1, 1981·Thrombosis Research·D CoppeE Salzman
Jul 1, 1980·Archives of Otolaryngology·J Jerger, J Hall

❮ Previous
Next ❯

Citations

Jan 1, 1995·Cancer Chemotherapy and Pharmacology·N A DobbsR D Rubens
Jul 25, 2003·European Journal of Drug Metabolism and Pharmacokinetics·B H Ali
Jan 1, 1987·Pharmacology & Therapeutics·F M Williams
Jan 1, 1991·Pharmacology & Therapeutics·J O Miners, P I Mackenzie
Dec 1, 1993·Pharmacology & Therapeutics·M J Seaton, E S Vesell
Jul 1, 1990·British Journal of Clinical Pharmacology·H MönigH M Schulte
Aug 1, 1995·British Journal of Clinical Pharmacology·K M KnightsJ O Miners
Oct 24, 1998·Clinical and Experimental Pharmacology & Physiology·K M Knights
Jan 1, 1991·Fundamental & Clinical Pharmacology·N BarzaghiN Marchese
Jun 1, 2011·Journal of Nutrigenetics and Nutrigenomics·Sandi L NavarroJohanna W Lampe
Jan 29, 2014·Journal of Cardiovascular Translational Research·Rossella MarcucciRosanna Abbate
Jun 11, 2005·Cancer Causes & Control : CCC·Julie A BakerKirsten B Moysich
Jul 27, 2006·Expert Opinion on Drug Metabolism & Toxicology·Obiamiwe C Umeh, Judith S Currier
Apr 13, 2007·Expert Opinion on Drug Metabolism & Toxicology·Kathleen M KnightsJohn O Miners
Dec 1, 1990·American Journal of Obstetrics and Gynecology·A T Teichmann
Oct 1, 1989·British Journal of Clinical Pharmacology·S G OwenH W Francis
Sep 1, 2006·Environmental Toxicology and Pharmacology·Mustafa Al-ZoughoolGlenn Talaska
Apr 15, 2015·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Ana Cuesta-GrageraMarival Bermejo
Mar 23, 2017·European Heart Journal. Cardiovascular Pharmacotherapy·J TamargoS Agewall
Jan 7, 1999·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·M A Benedito
Aug 1, 1988·Baillière's Clinical Rheumatology·R O DayK M Williams
Dec 1, 1993·Biopharmaceutics & Drug Disposition·H Cheng, W J Jusko
Dec 24, 2008·Women's Health·Jen Richardson, Anita Holdcroft
Sep 7, 2006·AIDS·Francesca T AweekaUNKNOWN NIAID AIDS Clinical Trials Group
Feb 24, 2006·Nature Reviews. Cancer·Cornelia M UlrichJohn D Potter
Jul 6, 2005·European Heart Journal·Nicoline JochmannVerena Stangl
Jul 15, 2017·Journal of Applied Physiology·Stephen M RatchfordTodd A Trappe

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.